Safety and effectiveness of bevacizumab (BV) plus chemotherapy (CT) in elderly patients with mCRC: results from the BRiTE registry

被引：0
|
作者：
Sugrue, M. [1 ]
Kozloff, M. [2 ]
Hainsworth, J. [3 ]
Badarinath, S. [4 ]
Cohn, A. [5 ]
Flynn, P. [6 ]
Dong, W. [7 ]
Purdie, D. [7 ]
Yi, J. [7 ]
Grothey, A. [8 ]
机构：
[1] Univ Calif San Francisco, Genentech Inc, San Francisco, CA 94143 USA
[2] Univ Chicago, Ingalls Hosp Harvey IL, Harvey, KS USA
[3] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[4] Florida Oncol Assoc, Jacksonville, FL USA
[5] Rocky Mountain Canc Ctr, Denver, CO USA
[6] Metro Minnesota CCOP, St Louis, MO USA
[7] Genentech Inc, San Francisco, CA USA
[8] Mayo Clin, Rochester, MN USA
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70976-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3048
引用
收藏
页码：250 / 250
页数：1
相关论文
共 50 条
  • [1] Safety and effectiveness of bevacizumas (BV) plus chemotherapy (CT) in elderly patients with MCRC: Results from the brite registry
    Sugrue, M.
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Dong, W.
    Suzuki, S.
    Purdie, D.
    Grothey, A.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : VII87 - VII87
  • [2] Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients with metastatic colorectal cancer (MCRC): Results from the BRiTE observational cohort study
    Kozloff, M.
    Sugrue, M.
    Chiruvolu, P.
    Purdie, D.
    Berlin, J.
    Flynn, P.
    Kabbinavar, F.
    Sargent, D.
    Dong, W.
    Grothey, A.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 26 - 26
  • [3] Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): Results from the BRiTE observational cohort study
    Kozloff, M. F.
    Sugrue, M. M.
    Purdie, D. M.
    Berlin, J. D.
    Flynn, P. J.
    Kabbinavar, F. F.
    Sargent, D. J.
    Dong, W.
    Grothey, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] SAFETY OUTCOMES ASSOCIATED WITH LONG-TERM, CONTINUOUS EXPOSURE TO BEVACIZUMAB (BV) AND CHEMOTHERAPY (CT) IN PATIENTS (PTS) WITH MCRC: RESULTS FROM THE BRITE OBSERVATIONAL COHORT STUDY
    Kozloff, M.
    Berlin, J.
    Flynn, J.
    Grothey, A.
    Kabbinavar, F.
    Sargent, D.
    Dong, W.
    Purdie, D.
    Sugrue, M.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 132 - 132
  • [5] A cost-effectiveness analysis of bevacizumab (BV) plus chemotherapy (CT) versus aflibercept (AFLI) plus CT in patients with metastatic colorectal cancer (mCRC) previously treated with BV
    Morlock, Robert
    Yu, Elaine
    Ray, Joshua
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [6] Serious arterial thromboembolic events (sATE) in patients (PTS) with metastatic colorectal cancer (MCRC) treated with bevacizumab (BV): Results from the BRiTE registry
    Sugrue, M.
    Yi, J.
    Purdie, D.
    Dong, W.
    Grothey, A.
    Kozoff, M.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : VII30 - VII30
  • [7] Serious arterial thromboembolic events (sATE) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV): Results from the BRiTE registry
    Sugrue, M. M.
    Yi, J.
    Purdie, D.
    Dong, W.
    Grothey, A.
    Kozloff, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): Preliminary results from a larger registry in the US
    Kozloff, M
    Cohn, A
    Christiansen, N
    Flynn, P
    Kabbinavar, F
    Robles, R
    Yood, MU
    Sarkar, S
    Hambleton, J
    Grothey, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 262S - 262S
  • [9] Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE).
    Hedrick, E.
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Dong, W.
    Suzuki, S.
    Sugrue, M.
    Grothey, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 155S - 155S
  • [10] Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer (MCRC) treated with bevacizumab (BV) plus chemotherapy (CT)
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Dong, W.
    Suzuki, S.
    Purdie, D.
    Yi, J.
    Sugrue, M.
    Grothey, A.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : VII80 - VII80
12345